5 Stocks To Buy Next Week Where Brokerages Have “Buy” Call

Here are a list of 5 stocks that have been recommended by brokers, during the week. These could be good to buy next week and hold for the long-term.

Century Plyboards

ICICI Securities has a buy call on the stock of Century Plyboards for a price target of Rs 775. "The company is a play on the growing interior infrastructure market in India. With its comprehensive product portfolio, strong brand and wide distribution reach, the company is well placed to capitalise on demand pick-up in the housing sector. Company is expected to witness revenue/PAT CAGRs of 16.9%/17.8% over FY22- FY25E with a strong balance sheet and impressive return ratios. We continue to like CPBI for its comprehensive product portfolio, wide distribution and strong brand name. Maintain BUY with an unchanged Dec'23E target price of Rs775, set at 35x 1-year forward Pe," the brokerage has said.

Buy Healthcare Global, says ICICI Securities

ICICI Securities has a buy call on the stock of Healthcare Global with a price target of Rs 360 per share. "Comfortable debt levels with negligible capex plans provide room to explore additional growth opportunities. We remain positive on the stock as the company is poised for growth with focus on improving the utilisation of its assets and strengthening the balance sheet. Retain BUY with target price of Rs360/share based on 15xSep'24E EV/EBITDA," the brokerage has said.

V-Guard

ICICI Direct has a "buy: call on V-Guard with a price target of Rs 310. "We build in EBITDA margin of 10.1% and 11% for FY24E and FY25E, respectively. PAT is likely to grow at CAGR of ~18% in FY22-25E tracking higher sales growth and recovery in EBITDA margin post acquisition of the Sunflame business. We roll over our valuation on FY25E and revise our rating on V-Guard from HOLD to BUY. We value the company at 35x FY25E earnings with a revised target price of | 310 per share," the brokerage has said.

Dalmia Bharat

ICICI Securities has recommended buying Dalmia Bharat with a price target of Rs 2200. "We increase our FY23E/FY24E EBITDA estimates by ~5%/6% and raise our target price to Rs 2,200 per share (earlier: Rs2,000) based on 11x Dec'24E EV/E on quarterly rollover. Maintain BUY. Key risks: Lower demand/price and higher costs," the brokerage has said ion its report.

Manappuram Finance

Monarch Capital has a "buy" call on Manappuram Finance with a price target of Rs 160 on the stock. "In our last note, we had highlighted the need for a definitive strategy around RoE-AUM in the gold loan portfolio. Albeit at a nascent stage, recent results and management commentaries hint at realigning to the same. This coupled with the cyclical upcycle in the non-gold loan portfolio will push consolidated RoE towards 18%+. Valuations at 0.8x FY25E ABV are inexpensive, when there are clear signs of a cyclical and strategic upswing. Retain BUY with TP at Rs160 (SOTP based valuation). Our upside case TP is at Rs180," the brokerage has said.

According to it, the key risks are lower than expected growth in the non-gold portfolio, return in stance towards growth in gold loan AUM or margin pressure.